DexCom, Inc. (NASDAQ:DXCM) Director Steven R. Altman Sells 1,000 Shares

DexCom, Inc. (NASDAQ:DXCM) Director Steven R. Altman sold 1,000 shares of DexCom stock in a transaction that occurred on Friday, September 15th. The shares were sold at an average price of $101.50, for a total value of $101,500.00. Following the sale, the director now directly owns 61,700 shares in the company, valued at approximately $6,262,550. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

DexCom Trading Down 1.2 %

Shares of NASDAQ DXCM traded down $1.13 during trading hours on Tuesday, reaching $94.16. The stock had a trading volume of 3,644,366 shares, compared to its average volume of 2,849,918. DexCom, Inc. has a 52-week low of $78.94 and a 52-week high of $139.55. The firm has a market cap of $36.52 billion, a price-to-earnings ratio of 109.72, a P/E/G ratio of 1.82 and a beta of 1.12. The business’s fifty day moving average price is $114.89 and its two-hundred day moving average price is $118.10. The company has a current ratio of 2.42, a quick ratio of 2.21 and a debt-to-equity ratio of 1.16.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, July 27th. The medical device company reported $0.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.22 by $0.12. The business had revenue of $871.30 million for the quarter, compared to the consensus estimate of $841.16 million. DexCom had a return on equity of 22.01% and a net margin of 11.18%. The business’s revenue was up 25.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.17 EPS. Analysts expect that DexCom, Inc. will post 1.23 EPS for the current fiscal year.

Hedge Funds Weigh In On DexCom

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Avalon Trust Co purchased a new stake in DexCom during the first quarter worth $26,000. Whittier Trust Co. increased its position in shares of DexCom by 684.4% during the first quarter. Whittier Trust Co. now owns 251 shares of the medical device company’s stock worth $29,000 after purchasing an additional 219 shares in the last quarter. Atlas Capital Advisors LLC purchased a new stake in shares of DexCom during the 2nd quarter valued at $33,000. CoreCap Advisors LLC purchased a new position in DexCom during the 4th quarter worth $35,000. Finally, TFC Financial Management Inc. increased its position in DexCom by 4,814.3% during the 1st quarter. TFC Financial Management Inc. now owns 344 shares of the medical device company’s stock valued at $40,000 after buying an additional 337 shares in the last quarter. 93.88% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Canaccord Genuity Group increased their price objective on shares of DexCom from $135.00 to $150.00 and gave the company a “buy” rating in a report on Friday, July 28th. Piper Sandler lifted their price objective on DexCom from $150.00 to $160.00 and gave the stock an “overweight” rating in a research note on Friday, July 28th. Morgan Stanley initiated coverage on DexCom in a research report on Tuesday, May 30th. They set an “equal weight” rating and a $131.00 target price for the company. Robert W. Baird reduced their price target on shares of DexCom from $153.00 to $130.00 and set an “outperform” rating on the stock in a research report on Monday, August 21st. Finally, Barclays increased their price objective on shares of DexCom from $115.00 to $138.00 and gave the company an “equal weight” rating in a research report on Monday, July 31st. Three equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $136.31.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices for specific and permitted use cases, including non-medical device applications, medical device data analysis, integrated continuous glucose monitoring systems (iCGM) secondary display alarms, active patient monitoring, and treatment decisions; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.